Accepted tenets of molecular targeting of EGFR signaling in ovarian and non-ovarian cancers encompass small molecule TKIs (e.g., erlotinib, gefitinib), ATP-binding site inhibitors (e.g., CI-1033), anti-EGFR/ErbB2monoclonal antibodies (e.g., matuzumab, pertuzumab, cetuximab, trastuzumab), and multikinase inhibitors (e.g., vandetanib, sorafenib) [164, 166, 174, 184–194]. Here, EGFR is linked to ovarian carcinoma.